Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 23, 2024 (filed on Apr 25, 2024)Insider Name:Maetzold Derek JOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-69Price:$20.11
-
Apr 23, 2024 (filed on Apr 25, 2024)Insider Name:Maetzold Derek JOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-69Price:$20.11
-
Apr 23, 2024 (filed on Apr 25, 2024)Insider Name:Maetzold Derek JOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-69Price:$20.11
-
Apr 23, 2024 (filed on Apr 25, 2024)Insider Name:Maetzold Derek JOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-68Price:$20.11
-
Apr 23, 2024 (filed on Apr 25, 2024)Insider Name:Maetzold Derek JOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-215Price:$20.11
-
Apr 23, 2024 (filed on Apr 25, 2024)Insider Name:Maetzold Derek JOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-215Price:$20.11
-
Apr 23, 2024 (filed on Apr 25, 2024)Insider Name:Maetzold Derek JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-421Price:$20.11
-
Apr 12, 2024 (filed on Apr 16, 2024)Insider Name:Maetzold Derek JOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-317Price:$20.35
-
Apr 12, 2024 (filed on Apr 16, 2024)Insider Name:Maetzold Derek JOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-317Price:$20.35
-
Apr 12, 2024 (filed on Apr 16, 2024)Insider Name:Maetzold Derek JOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-317Price:$20.35
Filings by filing date
-
Apr 23, 2024 (filed on Apr 25, 2024)Insider Name:Maetzold Derek JOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-69Price:$20.11
-
Apr 23, 2024 (filed on Apr 25, 2024)Insider Name:Maetzold Derek JOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-69Price:$20.11
-
Apr 23, 2024 (filed on Apr 25, 2024)Insider Name:Maetzold Derek JOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-69Price:$20.11
-
Apr 23, 2024 (filed on Apr 25, 2024)Insider Name:Maetzold Derek JOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-68Price:$20.11
-
Apr 23, 2024 (filed on Apr 25, 2024)Insider Name:Maetzold Derek JOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-215Price:$20.11
-
Apr 23, 2024 (filed on Apr 25, 2024)Insider Name:Maetzold Derek JOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-215Price:$20.11
-
Apr 23, 2024 (filed on Apr 25, 2024)Insider Name:Maetzold Derek JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-421Price:$20.11
-
Apr 12, 2024 (filed on Apr 16, 2024)Insider Name:Maetzold Derek JOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-317Price:$20.35
-
Apr 12, 2024 (filed on Apr 16, 2024)Insider Name:Maetzold Derek JOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-317Price:$20.35
-
Apr 12, 2024 (filed on Apr 16, 2024)Insider Name:Maetzold Derek JOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-317Price:$20.35
News
Biz Brief
Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 505 S Friendswood Drive 2014 SAN MIGUEL DR FRIENDSWOOD TX 77546 |
Tel: | N/A |
Website: | https://castlebiosciences.com |
IR: | See website |
Key People | ||
Derek J. Maetzold President, Chief Executive Officer, Founder, Director | Frank Stokes Chief Financial Officer | Kristen M. Oelschlager Chief Operating Officer | Tobin W. Juvenal Chief Commercial Officer |
Business Overview |
Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other. |
Financial Overview |
For the fiscal year ended 31 December 2023, Castle Biosciences Inc revenues increased 60% to $219.8M. Net loss decreased 14% to $57.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest and other non-operating income increase from $4M to $10.6M (income), Depreciation in R&D decrease of 2% to $330K (expense). |
Employees: | 610 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $295.22M as of Dec 31, 2023 |
Annual revenue (TTM): | $219.79M as of Dec 31, 2023 |
EBITDA (TTM): | -$55.65M as of Dec 31, 2023 |
Net annual income (TTM): | -$57.47M as of Dec 31, 2023 |
Free cash flow (TTM): | -$19.25M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 27,587,062 as of Apr 2, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |